Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women

Arthritis and Rheumatism

Volumn 52, Issue 6, 2005, Pages 1655-1664

  Fernández, Mónica ^a   Calvo Alén, Jaime ^a   Alarcón, Graciela S ^a,d   Roseman, Jeffrey M ^a   Bastian, Holly M ^a   Fessler, Barri J ^a   McGwin Jr , Gerald ^a   Vilá, Luis M ^b   Sanchez, Martha L ^a   Reveille, John D ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

^c UNIVERSITY OF TEXAS   (United States)

^d 830 Faculty Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; AMENORRHEA; ARTICLE; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ETHNOLOGY; FEMALE; HISPANIC; HORMONE SUBSTITUTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; VASCULAR DISEASE;

ADULT; AGE FACTORS; AGE OF ONSET; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENOPAUSE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; UNITED STATES; VASCULAR DISEASES;

EID: 20744432176     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21048     Document Type: Article

References (51)

1. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999;42:1274-80.
2. Mok CC, Lau CS, Ho CT, Wong RW. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 1999;28:357-62.
3. Sanchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Diaz J, Moreno-Coutino G, Cravioto MC. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. Am J Med 2001;111:464-8.
4. Wen C, Li LS. Blood levels of sex hormone in lupus nephritis and their relationship to lupus activity. Chin Med J (Engl) 1993;106: 49-52.
5. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:951-68.
6. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci U S A 2000;97:2703-8.
7. Tsokos GC, Wong HK, Enyedy EJ, Nambiar MP. Immune cell signaling in lupus. Curr Opin Rheumatol 2000;12:355-63.
8. Lahita RG. The importance of estrogens in systemic lupus erythematosus. Clin Immunol Immunopathol 1992;63:17-8.
9. Evans MJ, MacLaughlin S, Marvin RD, Abdou NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-α production in SLE but not in normal cultures. Clin Immunol Immunopathol 1997;82:258-62.
10. Roubinian JR, Talal N, Greenspan JS, Goodman JR. Siiteri PK. Effect of castration and sex hormone treatment on survival, anti nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978;147:1568-83.
11. Yoshida S, Castles JJ, Gershwin ME. The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 1990;19: 224-42.
12. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnie groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197-209.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
14. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
15. US Department of Commerce, Bureau of the Census. Current population reports, series P-23, no. 28 and series P-60, no. 68 and subsequent years. Washington, DC: Housing and Household Economic Statistics Division; 1995.
16. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
17. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
18. Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975;254:505-15.
19. Hamilton RG, Harley JB, Bias WB, Roebber M, Reichlin M, Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus: correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505.
20. Harris EN. Special report: the second international anti-cardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990;94: 476-84.
21. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:7S7-93.
22. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995;38: 1260-70.
23. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
24. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003;62:556-60.
25. Blatt NB, Glick GD. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacol Ther 1999;83:125-39.
26. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and The European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine (Baltimore) 1993;72:113-24.
27. Jonsson H, Nived O, Sturfelt G. The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus. J Rheumatol 1988;15:505-9.
28. Wilson HA, Hamilton ME, Spyker DA, Brunner CM, O'Brien WM, Davis JS IV, et al. Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum 1981;24:1230-5.
29. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-80.
30. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50:36-42.
31. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
32. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
33. Vandewalle B, Lefebrre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46.
34. Weidler C, Harle P, Schedel J, Schmidt M, Scholmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol 2004;31: 489-94.
35. Goemaere S, Ackerman C, Goethals K, de Keyser F, van der Straeten C, Verbruggen G, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990;17:1620-2.
36. Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986;29:1501-9.
37. Cevik R, Em S, Gur A, Nas K, Sarac AJ, Colpan L. Sex and thyroid hormone status in women with rheumatoid arthritis: are there any effects of menopausal state and disease activity on these hormones? Int J Clin Pract 2004;58:327-32.
38. Robinzon B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatol (Oxford) 1999;38:488-95.
39. Ostensen M, Villiger PM. Immunology of pregnancy: pregnancy as a remission inducing agent in rheumatoid arthritis. Transpl Immunol 2002;9:155-60.
40. Castagnetta LA, Carruba G, Granata OM, Stefano R, Miele M. Schmidt M, et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol 2003;30:2597-605.
41. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002;966:238-46.
42. Suzuki T, Schaumberg DA, Sullivan BD, Liu M, Richards SM, Sullivan RM, et al. Do estrogen and progesterone play a role in the dry eye of Sjögren's syndrome? Ann N Y Acad Sci 2002;966:223-5.
43. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50: 3947-57.
44. Sander GE, Giles TD. Cardiovascular complications of collagen vascular disease. Curr Treat Options Cardiovasc Med 2002;4: 151-9.
45. Rossouw JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
46. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Women's Health Initiative investigators: estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
47. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc 2002;288:49-57.
48. Katz RJ, Hsia J, Walker P, Jacobs H, Kessler C. Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors. Am J Cardiol 1996;78:876-80.
49. Salpeter S, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804.
50. Stencheber M, Droegemueller W, Herbst A, Misnell D. Menopause. In: Stencheber M, editor. Comprehensive gynecology. St. Louis: Mosby; 2000. p. 1217-50.
51. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.